A significant body of work from the Smyth group performed in various mouse cancer models suggests that CD96 might limit NK cell-mediated protection against metastases and, therefore, blocking CD96 would enhance NK cell production of IFN-γ and cancer control [44,69,70]. This evidence concerns the gene CD96 and cancer.